
Commentary|Videos|January 30, 2025
Approaching First-Line Treatment Decisions in Pediatric ALL
Author(s)George Yaghmour, MD, Rachel Elizabeth Rau, MD
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss first-line treatment considerations for pediatric ALL.
Advertisement
Episodes in this series

Advertisement
Related to this article

Maintenance galinpepimut-S extended overall survival in transplant-ineligible AML in second or later remission.

The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
3
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
4
Defining High-Risk Localized Prostate Cancer and the DASL-HiCaP Trial
5

